Clinical Trial Update: Erythropoetin Neuroprotection for Neonatal Cardiac Surgery [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on erythropoietin for neuroprotection in neonatal cardiac surgery (Phase 1/2) completed with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Aortic Arch Hypoplasia or Interruption
• Congenital Heart Disease
• Hypoplastic Left Heart Syndrome
• Transposition of the Great Arteries

Drugs mentioned

• Erythropoietin (erythropoietin)

Snippet

Sponsor: Baylor College of Medicine | Conditions: Congenital Heart Disease, Hypoplastic Left Heart Syndrome | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-05-19